{"filings":[{"id":99180,"accession_number":"0001477932-26-002227","cik":846377,"company_name":"Totaligent, Inc.","ticker":"TGNT","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Totaligent acquires Aetherium Medical ($10M rev); Klarich President, board member","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Totaligent forms subsidiary Aetherium Medical LLC; Klarich contributes trade secrets, know-how, and business network.","Ivan Klarich appointed President immediately, will join 3-member Board after closing.","Initial 10% fully-diluted equity (Series D Preferred) issued at closing; additional milestone-based equity.","Underlying Aetherium platform generated ~$10M annual revenue with >15 years consistent profitability.","No cash consideration; equity-only. Separate GloMed JV is not a condition of this agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7175783.297872341,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115036,"accession_number":"0001477932-26-001611","cik":846377,"company_name":"Totaligent, Inc.","ticker":"TGNT","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Totaligent extends GloMed joint venture LOI deadline to April 22, 2026","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Extension Amendment moves target closing date from March 22 to April 22, 2026.","Binding exclusivity period extended through April 22, 2026.","Delay attributed to ongoing due diligence and negotiations for definitive agreements.","All other terms of the original LOI remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7175783.297872341,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115035,"accession_number":"0001477932-26-001548","cik":846377,"company_name":"Totaligent, Inc.","ticker":"TGNT","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Totaligent extends target date for Aetherium Medical acqui-hire to April 10, 2026","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Extension Amendment moves negotiation and closing deadline from March 5, 2026 to April 10, 2026.","Exclusivity period with Aetherium Medical extended through April 10, 2026.","Transaction involves Totaligent acquiring Aetherium's team, IP, and assets in exchange for equity.","Delay attributed to ongoing due diligence and preparatory matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7175783.297872341,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115034,"accession_number":"0001477932-26-001167","cik":846377,"company_name":"Totaligent, Inc.","ticker":"TGNT","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Totaligent extends target closing date for Aetherium Medical acqui-hire to March 20, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extension Amendment moves target date for definitive agreements and closing from March 5 to March 20, 2026.","Exclusivity period under the LOI remains in effect through April 5, 2026.","Previously disclosed LOI on Feb 12, 2026, for acqui-hire of Aetherium team and IP in exchange for equity.","Only the target timeline changed; all other LOI terms unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":7175783.297872341,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115033,"accession_number":"0001477932-26-001016","cik":846377,"company_name":"Totaligent, Inc.","ticker":"TGNT","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Totaligent signs binding LOI for JV with GloMed and call option to acquire GloMed for $3M cash + 15% equity","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["GloMed has ~$10M annual revenue and ~$1M free cash flow; distributes biologics/devices in APAC via 20+ KOLs.","JV will combine Aetherium Medical platform with GloMed's infrastructure; no upfront cash; incremental revenue shared.","Call option to buy 100% of GloMed within 1 year for $3M cash plus 15% of Totaligent's fully diluted common stock.","Target JV closing March 22, 2026; subject to due diligence, definitive agreements, and PCAOB audit for option exercise.","Exclusivity through April 22, 2026; board seats: DeFeudis, Heath, Klarich; Totaligent appoints 3 seats for strategic control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7175783.297872341,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115032,"accession_number":"0001477932-26-000765","cik":846377,"company_name":"Totaligent, Inc.","ticker":"TGNT","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Totaligent enters acqui-hire LOI with Aetherium Medical; 10% equity stake, no cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquiring Aetherium's team, IP, business plan in exchange for 10% of Totaligent's outstanding common stock as restricted preferred.","New wholly owned subsidiary Aetherium Medical LLC formed; Assets contributed with no cash consideration at closing.","Ivan Klarich, Aetherium's CEO, appointed Managing Director of the subsidiary.","Target closing March 5, 2026; exclusivity through April 5, 2026; definitive agreements to follow.","Equity subject to milestone-based vesting, 15% escrow holdback for 12 months, and repurchase rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7175783.297872341,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148013,"accession_number":"0001477932-25-006639","cik":846377,"company_name":"Totaligent, Inc.","ticker":"TGNT","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Totaligent enters IR/PR consulting agreement; issues 5M shares as compensation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with 247MarketNews for six-month IR/PR services starting Sept 8, 2025.","Compensation: 5,000,000 restricted common shares, deliverable March 9, 2026.","Services include press releases, editorials, and distribution to 5,000+ investor endpoints.","Shares issued under Section 4(a)(2) exemption; no registration.","Agreement contains confidentiality, indemnification, and termination provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7175783.297872341,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166747,"accession_number":"0001477932-25-002877","cik":846377,"company_name":"Totaligent, Inc.","ticker":"TGNT","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Totaligent enters conversion limitation agreement with Karolus Maximus Kapital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement limits conversion of ~20 promissory notes so investor cannot own >4.99% of outstanding common stock.","Majority of the notes are past their stated maturity dates and remain outstanding.","Limitation cannot be waived unless investor gives company at least 61 days' written notice.","Agreement does not amend other terms of the convertible notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7175783.297872341,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166746,"accession_number":"0001477932-25-002874","cik":846377,"company_name":"Totaligent, Inc.","ticker":"TGNT","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Brian Heckathorne elected director, Ben Hansel resigns from Totaligent board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ben Hansel resigned as director effective April 18, 2025; departure not due to any disagreement with company.","Brian Heckathorne elected to board effective same date; he is a company founder with over 20 years in IT and digital marketing.","No compensatory arrangement in place for Heckathorne at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7175783.297872341,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}